Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796133 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women
A Phase 2 study of Ovulation, sponsored by Population Council.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT00796133 is a Phase 2 study of Ovulation that has completed, run by Population Council. The registered enrollment target is 18 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT00796133, a Phase 2 study of Ovulation, has completed, sponsored by Population Council.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.
Conditions Studied
Interventions
- DRUG NES/E2 gel
Study Locations (3)
Other
- Instituto Chileno de Medicina Reproductiva - Santiago
- Profamilia - Santo Domingo
California
- Women's and Children's Hospital; LA County/USC Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796133
The ClinicalTrials.gov registry entry for NCT00796133 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Population Council, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovulation appearing as the primary indexed condition, and to 1 intervention - of which NES/E2 gel is the first listed.
NCT00796133 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT00796133 about?
NCT00796133 is a clinical study titled "A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women". This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.
What is the current status of trial NCT00796133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-11. Estimated completion is 2014-01.
What conditions does trial NCT00796133 study?
This clinical trial studies the following conditions: Ovulation.
What interventions are being tested in trial NCT00796133?
The interventions under investigation include: NES/E2 gel (DRUG).
Who is sponsoring clinical trial NCT00796133?
This trial is sponsored by Population Council, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00796133 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovulation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.